DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) and Conduit Pharmaceuticals (NASDAQ:CDT – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, valuation, profitability, institutional ownership, risk and analyst recommendations.
Profitability
This table compares DiaMedica Therapeutics and Conduit Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| DiaMedica Therapeutics | N/A | -43.67% | -40.81% |
| Conduit Pharmaceuticals | N/A | N/A | -328.67% |
Valuation and Earnings
This table compares DiaMedica Therapeutics and Conduit Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| DiaMedica Therapeutics | N/A | N/A | -$19.38 million | ($0.56) | -11.16 |
| Conduit Pharmaceuticals | N/A | N/A | -$540,000.00 | N/A | N/A |
Analyst Recommendations
This is a breakdown of current ratings and target prices for DiaMedica Therapeutics and Conduit Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| DiaMedica Therapeutics | 0 | 0 | 3 | 0 | 3.00 |
| Conduit Pharmaceuticals | 0 | 0 | 0 | 1 | 4.00 |
DiaMedica Therapeutics currently has a consensus target price of $7.00, indicating a potential upside of 12.00%. Given DiaMedica Therapeutics’ higher probable upside, research analysts plainly believe DiaMedica Therapeutics is more favorable than Conduit Pharmaceuticals.
Institutional & Insider Ownership
10.1% of DiaMedica Therapeutics shares are owned by institutional investors. Comparatively, 3.3% of Conduit Pharmaceuticals shares are owned by institutional investors. 7.2% of DiaMedica Therapeutics shares are owned by company insiders. Comparatively, 30.9% of Conduit Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Risk & Volatility
DiaMedica Therapeutics has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500. Comparatively, Conduit Pharmaceuticals has a beta of 2.18, indicating that its stock price is 118% more volatile than the S&P 500.
Summary
Conduit Pharmaceuticals beats DiaMedica Therapeutics on 6 of the 10 factors compared between the two stocks.
About DiaMedica Therapeutics
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
About Conduit Pharmaceuticals
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
